logo-loader
viewIncanthera Ltd

Incanthera eyes huge market for cancer-prevention suncream

Snapshot

The company is a spin-out from Bradford University’s Institute of Cancer Therapeutics

ImmuPharma PLC -

Quick facts: Incanthera Ltd

Price: 16 GBX

AQSE:INC
Market: AQSE
Market Cap: -
Follow
  • Incanthera joined Aquis Exchange in February
  • Raised £1.2mln ahead of IPO  
  • Has developed novel cream, Sol, to treat and prevent skin cancer.

How it’s doing

Sol, the cream, has already gone through the proof of concept stage and Incanthera (LON:INC) is looking for a partner to help it through the product development and marketing stage.

The technology uses a proprietary formulation and prodrug targeting technologies to deliver treatment specifically to the tumour.

Originally a spin-out from Bradford University’s Institute of Cancer Therapeutics, the aim is to find a commercial partner for Sol within 12-18 months.

Incanthera has also rights to a portfolio of ICT’s other cancer-targeting therapeutics and will use partnerships to take other candidates from this portfolio to market.

Aim-listed biotech Immupharma PLC (LON:IMM) has an 11.9% stake and warrants at the listing price of 9.5p plus an option to subscribe for a further £250,000 worth of shares by end October.

Financial results for the twelve months ended March 31, 2020, showed an operating loss of £1.12mln and the group ended the period with £392,000 of cash.

What the boss says: Simon Ward, CEO

Sol has huge potential in both the therapeutic and cosmetic markets, where it can help remove Solar Keratoses, which are a common cause of skin cancer, as well as being a preventative application.

Watch the latest video

What the broker says

Research house Hardman says Incanthera offers distinct technology with the potential to attract the attention of the majors, especially given management’s strategy to out-license products early.

"The focus, initially, will be on Sol, a patent-protected, value-added, sun cream, which represents a relatively quick and low-risk cosmetics project.

"The current enterprise value (EV) suggests that there is good upside potential when comparing the company with a group of UK-listed peers working in the same field."

 

 

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera Ltd named herein, including the promotion by the Company of Incanthera Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Incanthera says it's making great progress towards commercialisation of lead...

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of its first set of results since listing earlier this year on the AQSE Growth Market. CEO ward describes it as a pivotal year for the company and says they're now fully focused on further development...

on 15/6/20

2 min read